Skip to content

Clinical significance of Malnutrition-Inflammation-Atherosclerosis Syndrome in the patients on maintenance hemodialysis

Clinical significance of Malnutrition-Inflammation-Atherosclerosis Syndrome in the patients on maintenance hemodialysis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN61950442
Enrollment
208
Registered
2007-09-06
Start date
2005-06-01
Completion date
Unknown
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease treated with hemodialysis. Urological and Genital Diseases End-stage renal disease

Interventions

Participants were randomised into 4 groups: 1. Current dialysis with atorvastatin (10 mg orally per day during the whole follow-up periode [24 months]) 2. Dialysis usin

Sponsors

Ministry of Science, Education and Sport of the Republic of Croatia
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: End-stage renal diasese on maintenance hemodialysis lasting at least 3 months.

Exclusion criteria

Exclusion criteria: 1. Previously transplanted 2. Previously treated with peritoneal dialysis 3. History of active infection in the last 3 months

Design outcomes

Primary

MeasureTime frame
1. Patient survival with or without MIA syndrome at 2 years 2. Survival of patient with MIA syndrome according to randomisation/intervention at 2 years

Secondary

MeasureTime frame
1. Determinantion of independent predictors of mortality in MIA syndrome patients at 2 years 2. Influence of intervention on laboratory parameters of MIA syndrome at 2 years 3. Safety assessement of atorvastatin application, checked after 1, 3, 6, 12 and 24 months according to known precautions for statin use 4. Hospitalisations rate and frequency of patients with or without MIA syndrome at 2 years

Countries

Croatia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026